Speedier drug approvals hit slowdown as FDA faces scrutiny
By MATTHEW PERRONE WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the...
Read More